Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Imonogas · 1 trial · 1 indication
Specific questionnaire with a 4 point scale
| Arm | Type | Description |
|---|---|---|
| Imonogas | EXPERIMENTAL | Imonogas 120 mg, 1 capsule three times daily for 8 weeks |
| Espumisan | ACTIVE_COMPARATOR | Espumisan 40 mg, 2 capsules four times daily for 8 weeks |
| Name | Type | Description |
|---|---|---|
| Imonogas | DRUG | Simethicone 120 mg in gel capsules |
| Espumisan | DRUG | Simethicone 40 mg in gel capsules |
Inclusion Criteria: 1. Subjects of the age of 18 years or older with a suspected diagnosis of functional dyspepsia according to Rome III criteria (see Appendix A) e.g. subjects suffering from bothersome postprandial fullness or early satiation or epigastric pain or epigastric burning AND no evidenc...
Imonogas is an investigational small molecule being developed for the treatment of functional dyspepsia, a gastrointestinal condition characterized by chronic indigestion symptoms. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
Imonogas is being developed by Johnson & Johnson, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker JNJ. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with functional dyspepsia.
Imonogas is in Phase 3 clinical development for functional dyspepsia. It is an investigational drug, meaning it has not yet received regulatory approval and is still undergoing clinical trials to assess its safety and effectiveness in the target patient population.
Imonogas has been studied in one completed Phase 3 clinical trial, identified as NCT02660372. This trial, titled 'Efficacy and Safety of Two Simeticone Brands in Adults With Functional Dyspepsia,' enrolled 210 participants in Russia and evaluated the drug's effects in adults aged 18 years and older.
Imonogas is being studied in a clinical trial that compares two brands of simeticone, a common anti-foaming agent used for digestive symptoms. However, the available information does not specify whether Imonogas itself is a simeticone product or a distinct compound being evaluated in the same trial context.